(1) I am not discussing the subject. I answered someone that something he was afraid of would NEVER happen.
(2) I would never assume anything with a pre-revenue biotech stock on the OTC. Changing management at this time would likely give you a new 52 week low. Not voting for additional authorized shared will also get you back to a 52 week low.
Management have taken this trial to the end. The incredible lack of patience is astonishing. We saw a glimpse of what to come. There's an ever increasing support from the neuro oncology community, which in the end will be the ones pushing for this treatment. We will see a hugely positive sentiment once they PR TLD and can tell their narrative. Will this bring the SP up to unrealistic levels? Likely not, but it will be an important stepping stone to approval and commercialization which is the ultimate goal, getting the drug to the patients. That will also get us to a realistic valuation of NWBO, which we will likely not get to until then, at least while still on the OTC. I understand everyone was expecting a 10 bagger here and now, but that will have to wait. Will we get there? I think there's a good chance we get a very nice valuation when we reach these goals. Until then, just turn off your computer and take some long walks. Enjoy life and be happy.
News 
Market Data 
Discover 
AI
